4 completed, 1 enrolling by invitation. 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Enrolling by invitation 1 |
Follow Mepolizumab 300 mg: new trials by email Literature Review of Mepolizumab 300 mg trials Research Report on Mepolizumab 300 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg - EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma | Phase 4 | Enrolling by invitation | Azienda Ospedaliero Universitaria di Cagliari | 90 | 2025-10-17 | 2026-01-15 |
| Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study) Mepolizumab 300 mg - Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA) | Completed | European EGPA Study Group | 591 | 2025-09-18 | 2026-09-11 | |
| Effectiveness on Sino-Nasal Symptoms Of Mepolizumab 300 Mepolizumab 300 mg - Sinus Disease, EGPA - Eosinophilic Granulomatosis With Polyangiitis | Completed | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 52 | 2025-09-12 | 2026-05-18 | |
| Mepo for Eosinophilic Esophagitis (EoE) Study Mepolizumab 300 mg, Mepolizumab 100 mg, Placebo - EoE, Eosinophilic Esophagitis | Phase 2 | Completed | University of North Carolina, Chapel Hill | 66 | 2019-03-20 | 2023-08-23 |
| Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone) - Hypereosinophilic Syndrome | Phase 3 | Completed | GlaxoSmithKline | 108 | 2017-03-07 | 2020-02-21 |
Churg-Strauss Syndrome (3) · Asthma (1) · Eosinophilic Esophagitis (1) · Hypereosinophilic Syndrome (1) · Paranasal Sinus Diseases (1) · Pulmonary Eosinophilia (1) · Vasculitis (1)
Azienda Ospedaliero Universitaria di Cagliari (1) · European EGPA Study Group (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · GlaxoSmithKline (1) · University of North Carolina, Chapel Hill (1)
Italy (4) · United States (2) · Argentina (1) · Belgium (1) · Brazil (1) · France (1) · Germany (1) · Mexico (1) · Poland (1) · Romania (1) · Russia (1) · Spain (1) · United Kingdom (1)
Eugenio De Corso (1) · Evan S Dellon, MD, MPH (1)
PMID 2202307, PMID 28514601, PMID 31719529, PMID 32638567, PMID 32956756, PMID 33001543, PMID 33011303, PMID 34347947, PMID 34389506, PMID 35106968, PMID 35493455, PMID 35568330, PMID 35850947, PMID 36091012, PMID 37064032, PMID 37161084, PMID 37423717, PMID 38251561